The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
使用Senolytic和抗纤维化药物提高骨髓干细胞对骨关节炎的有益作用
基本信息
- 批准号:10468269
- 负责人:
- 金额:$ 62.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:Adipose tissueAdultAftercareAgeAllograftingApoptosisApoptoticAspirate substanceAutologousBiological MarkersBiological Response Modifier TherapyBloodBone MarrowBone Marrow Stem CellCartilageCartilage DiseasesCell AgingCell DeathCellsChondrocytesClinicClinicalClinical DataClinical TrialsCombined Modality TherapyDataDegenerative polyarthritisDevelopmentDiseaseDouble-Blind MethodDrug usageFDA approvedFibrocartilagesFibrosisGoalsGrantHarvestHomeostasisHyaline CartilageImageImpairmentIn VitroIndividualInflammationInflammatoryInjuryInterventionInvestigationJointsKineticsKnee OsteoarthritisKnee jointLaboratoriesLosartanMagnetic Resonance ImagingMetabolicMorphologyMotionMusNatural regenerationOperative Surgical ProceduresOutcomePainPathway interactionsPatient Outcomes AssessmentsPatientsPeptide HydrolasesPharmaceutical PreparationsPhasePhase I/II TrialPhenotypePre-Clinical ModelProgressive DiseaseRandomizedRandomized Clinical TrialsRegimenReplacement ArthroplastyResearch InstituteResearch PersonnelResistanceSafetySignal TransductionSkeletal MuscleStructureSynovial FluidTechnologyTimeTissuesTransforming Growth Factor alphaTransforming Growth FactorsTransplantationTreatment EfficacyTreatment outcomeWorkadult stem celladult stem cell transplantationantifibrotic treatmentarmarthropathiesarticular cartilagebasecartilage degradationcartilage repaircell typechemokineclinical efficacyclinically translatablecytokinedesigndietary supplementsfisetinimplantationimprovedimproved outcomeinhibitorjoint destructionkinematicsloss of functionminimally invasivenovel strategiesosteochondral tissuepain outcomepatient populationpre-clinicalpreventregeneration potentialrepairedsenescencestem cell functionstem cell therapystem cellssymptom treatment
项目摘要
Abstract: Osteoarthritis (OA) is a progressive joint disease leading to cartilage damage, pain and loss of
function. While many stem cell therapies for OA are under investigation, none are currently FDA-approved for
modifying the course of the disease. Of the many adult stem cell types potentially applicable to OA, bone marrow
stem cells (BMSCs) from bone marrow aspirate concentrate (BMC) are the most clinically translatable (and are
already in clinical use) since they can be harvested using minimally invasive technology and do not require in
vitro expansion. There is, however, significant potential for improving efficacy of BMSC treatment for OA. The
number of senescent cells in BMC increases with age and OA, and these cells release pro-inflammatory
cytokines/chemokines, proteases, and other senescence-associated secretory phenotypes (SASP) that can
impair stem cell function and likely contribute to OA development/progression. Dr. Kirkland’s laboratory (co-
investigator) has identified compounds that specifically kill senescent cells, abrogating systemic SASP factors.
We have shown that these senolytic agents can delay OA in a preclinical model. We have also shown that
blocking fibrosis with Losartan (a TGF-β1blocker) can improve cartilage repair by promoting regeneration of
hyaline cartilage while reducing the amount of fibrocartilage. Thus, we hypothesize that administration of
senolytic and/or anti-fibrotic agents will enhance the beneficial effect of BMSCs for treating OA. We propose to
perform, a randomized clinical trial at The Steadman Clinic (TSC) and Steadman Philippon Research Institute
(SPRI). This phase I/II trial will evaluate the safety and efficacy of Fisetin (a senolytic dietary supplement) and
Losartan (an anti-fibrotic drug), used either individually or in combination, for improving the clinical efficacy of
BMSCs in the treatment of knee osteoarthritis. The senolytic (Fisetin 1000mg/day, previously FDA IND
approved) regimen will be cycles of 2 days on/28 days off, administered before and 3 months after BMSC
treatment. The anti-fibrotic (Losartan, 25mg/day, previously IND-exempted) will be administered for 30 days
starting immediately after BMSC treatment. OA knee joints will undergo MRI at baseline and 18 months post-
treatment to assess changes in cartilage morphology and structure over time. Patient-reported outcomes for
pain and function will be collected at baseline and 3, 6, 12 & 18 months. Joint and cartilage function will be
assessed using video-motion analysis at baseline and 18 months. OA biomarkers related to cartilage
degeneration, inflammation and pain will be assessed at baseline and 18 months. Blood and synovial fluid will
be evaluated at baseline, 4 days and 18 months after treatment to assess changes in cellular senescence and
OA biomarkers. This trial will build upon a currently active clinical trial on orthobiologics for OA treatment at
SPRI (utilizing the same patient population and outcomes assessments), demonstrating the ability of our teams
to perform the proposed study and also leveraging the combined trials to effectively provide a 6-arm,
comprehensive assessment of biological therapies for improving treatment of OA.
【摘要】:骨关节炎(OA)是一种进行性关节疾病,会导致软骨损伤、疼痛和关节功能丧失。
功能。虽然许多治疗 OA 的干细胞疗法正在研究中,但目前尚无 FDA 批准用于治疗 OA 的干细胞疗法。
改变病程。在许多可能适用于 OA 的成体干细胞类型中,骨髓
来自骨髓抽吸浓缩物 (BMC) 的干细胞 (BMSC) 最具临床可转化性(并且
已经在临床使用),因为它们可以使用微创技术收获,并且不需要
体外扩增。然而,BMSC 治疗 OA 的疗效具有巨大的潜力。这
BMC 中的衰老细胞数量随着年龄和 OA 的增加而增加,这些细胞释放促炎物质
细胞因子/趋化因子、蛋白酶和其他衰老相关的分泌表型 (SASP)
损害干细胞功能并可能导致 OA 的发生/进展。柯克兰博士的实验室(合作
研究人员)已经鉴定出能够特异性杀死衰老细胞、消除全身 SASP 因子的化合物。
我们已经在临床前模型中证明这些抗衰老药物可以延迟 OA。我们还表明
用氯沙坦(一种 TGF-β1 阻滞剂)阻断纤维化可以通过促进软骨再生来改善软骨修复
透明软骨同时减少纤维软骨的量。因此,我们假设管理
抗衰老剂和/或抗纤维化剂将增强 BMSC 治疗 OA 的有益效果。我们建议
在 Steadman Clinic (TSC) 和 Steadman Philippon 研究所进行的一项随机临床试验
(SPRI)。该 I/II 期试验将评估 Fisetin(一种 senolytic 膳食补充剂)的安全性和功效,以及
氯沙坦(一种抗纤维化药物),单独或联合使用,用于改善以下疾病的临床疗效
BMSCs 治疗膝骨关节炎。 senolytic(Fisetin 1000mg/天,之前已获得 FDA IND
批准的)方案将是 2 天/28 天休息的周期,在 BMSC 之前和之后 3 个月进行
治疗。抗纤维化药物(氯沙坦,25mg/天,之前已获得 IND 豁免)将持续 30 天
BMSC 治疗后立即开始。 OA 膝关节将在基线和术后 18 个月接受 MRI 检查
治疗以评估软骨形态和结构随时间的变化。患者报告的结果
将在基线以及 3、6、12 和 18 个月时收集疼痛和功能。关节和软骨功能将
在基线和 18 个月时使用视频运动分析进行评估。与软骨相关的 OA 生物标志物
将在基线和 18 个月时评估变性、炎症和疼痛。血液和滑液会
在基线、治疗后 4 天和 18 个月进行评估,以评估细胞衰老的变化和
OA 生物标志物。该试验将建立在目前正在进行的骨关节炎治疗骨生物制剂临床试验的基础上
SPRI(利用相同的患者群体和结果评估),展示了我们团队的能力
进行拟议的研究,并利用联合试验有效地提供 6 臂,
对改善 OA 治疗的生物疗法进行综合评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Johnny Huard其他文献
Johnny Huard的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Johnny Huard', 18)}}的其他基金
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
使用Senolytic和抗纤维化药物提高骨髓干细胞对骨关节炎的有益作用
- 批准号:
10044832 - 财政年份:2020
- 资助金额:
$ 62.11万 - 项目类别:
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
使用Senolytic和抗纤维化药物提高骨髓干细胞对骨关节炎的有益作用
- 批准号:
10416892 - 财政年份:2020
- 资助金额:
$ 62.11万 - 项目类别:
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
使用Senolytic和抗纤维化药物提高骨髓干细胞对骨关节炎的有益作用
- 批准号:
10688127 - 财政年份:2020
- 资助金额:
$ 62.11万 - 项目类别:
The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis
使用Senolytic和抗纤维化药物提高骨髓干细胞对骨关节炎的有益作用
- 批准号:
10401197 - 财政年份:2020
- 资助金额:
$ 62.11万 - 项目类别:
Effects of Circulating Factors and Progenitors on Wound Healing during Pregnancy
循环因子和祖细胞对妊娠期伤口愈合的影响
- 批准号:
9917947 - 财政年份:2019
- 资助金额:
$ 62.11万 - 项目类别:
Ablation of Non-Myogenic Progenitor Cells as a New Therapeutic Approach to Duchenne Muscular Dystrophy
消融非肌源性祖细胞作为杜氏肌营养不良症的新治疗方法
- 批准号:
10013124 - 财政年份:2019
- 资助金额:
$ 62.11万 - 项目类别:
Development of biological approaches to enhance skeletal muscle rehabilitation after anterior cruciate ligament injury
开发生物学方法来增强前十字韧带损伤后骨骼肌的康复
- 批准号:
9809778 - 财政年份:2019
- 资助金额:
$ 62.11万 - 项目类别:
Bone Abnormalities & Healing Defect in Muscular Dystrophy
骨骼异常
- 批准号:
9263882 - 财政年份:2014
- 资助金额:
$ 62.11万 - 项目类别:
The Use of Coacervate Technology as a New Drug Delivery System for Musculoskeleta
使用凝聚技术作为肌肉骨骼的新型药物输送系统
- 批准号:
8681855 - 财政年份:2014
- 资助金额:
$ 62.11万 - 项目类别:
The Use of Coacervate Technology as a New Drug Delivery System for Musculoskeleta
使用凝聚技术作为肌肉骨骼的新型药物输送系统
- 批准号:
9130004 - 财政年份:2014
- 资助金额:
$ 62.11万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 62.11万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 62.11万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 62.11万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 62.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 62.11万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 62.11万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 62.11万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 62.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 62.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 62.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




